Early Effects of Single and Low-Frequency Repeated Administration of Teriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats

[1]  A. Yamaguchi,et al.  Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. , 1997, The Journal of clinical investigation.

[2]  J. Heaf,et al.  Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  E. Opas,et al.  The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. , 1993, The Journal of clinical investigation.

[4]  A. Chines,et al.  Five Years of Treatment with Risedronate and its Effects on Bone Safety in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.

[5]  E. Bonucci,et al.  Osteocalcin, iPTH, alkaline phosphatase and hand X-ray scores as predictive indices of histomorphometric parameters in renal osteodystrophy. , 1990, Nephron.

[6]  C. Li,et al.  Estrogen and "Exercise" Have a Synergistic Effect in Preventing Bone Loss in the Lumbar Vertebra and Femoral Neck of the Ovariectomized Rat , 2002, Calcified Tissue International.

[7]  T. Sugimoto,et al.  Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women , 2012, Osteoporosis International.

[8]  J. Aubin,et al.  Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. , 1990, Endocrinology.

[9]  E. Lewiecki,et al.  Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  T. Nakamura,et al.  A novel synthetic vitamin D analogue, 2β-(3-hydroxypropoxy)1α, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats , 1994, Calcified Tissue International.

[11]  Lynn Wei,et al.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. , 1997, The Journal of clinical investigation.

[12]  R. L. Cain,et al.  Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. , 2001, Endocrinology.

[13]  Yili Lu,et al.  A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[14]  H. Takahashi,et al.  Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. , 1994, Bone.

[15]  R. Takagi,et al.  Intermittent PTH Administration Stimulates Pre‐Osteoblastic Proliferation Without Leading to Enhanced Bone Formation in Osteoclast‐Less c‐fos−/− Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  D. Black,et al.  The search for the optimal anabolic osteoporosis therapy , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  M. Inaba,et al.  Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment , 2004, Journal of Bone and Mineral Metabolism.

[18]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[19]  Y. Ma,et al.  Effects of prostaglandin E2 and F2 alpha on the skeleton of osteopenic ovariectomized rats. , 1995, Bone.

[20]  E. Canalis,et al.  Hormonal control of bone collagen synthesis in vitro: effects of parathyroid hormone and calcitonin. , 1976, Endocrinology.

[21]  P. Roberson,et al.  Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.

[22]  H. Ozawa,et al.  Osteocytic osteolysis observed in rats to which parathyroid hormone was continuously administered , 2004, Journal of Bone and Mineral Metabolism.

[23]  R. Eastell,et al.  Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. , 2009, Bone.

[24]  J. Bilezikian.  Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window , 2008, Current osteoporosis reports.

[25]  S. Gallacher,et al.  Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review , 2010, Calcified Tissue International.

[26]  J. Kanis,et al.  Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  K. Chihara,et al.  Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. , 2006, Endocrinology.

[28]  T. Sone,et al.  Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. , 2012, The Journal of clinical endocrinology and metabolism.

[29]  T. Sugimoto,et al.  Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis , 2013, Osteoporosis International.

[30]  N. Takahashi,et al.  Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  W. Jee,et al.  Effects of prostaglandin E2 and F2α on the skeleton of osteopenic ovariectomized rats , 1995 .

[32]  Three-Times-Weekly Administration of Teriparatide Improves Vertebral and Peripheral Bone Density, Microarchitecture, and Mechanical Properties Without Accelerating Bone Resorption in Ovariectomized Rats , 2015, Calcified Tissue International.

[33]  A. Yamaguchi,et al.  Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions , 2016, Journal of Bone and Mineral Metabolism.